# A Safety and Efficacy Study of MSI-1256F (Squalamine Lactate) To Treat "Wet" Age-Related Macular Degeneration

> **NCT00089830** · PHASE2 · TERMINATED · sponsor: **Genaera Corporation** · enrollment: 120 (—)

## Conditions studied

- Macular Degeneration

## Interventions

- **DRUG:** MSI-1256F (Squalamine Lactate)

## Key facts

- **NCT ID:** NCT00089830
- **Lead sponsor:** Genaera Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-08
- **Primary completion:** —
- **Final completion:** 2007-05
- **Target enrollment:** 120 (—)
- **Last updated:** 2007-11-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00089830

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00089830, "A Safety and Efficacy Study of MSI-1256F (Squalamine Lactate) To Treat "Wet" Age-Related Macular Degeneration". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT00089830. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*